Abstract
Interferon beta (IFNβ) treatment in multiple sclerosis (MS) has been associated with hepatotoxicity,1 and there have been reported cases of severe hepatitis induced by IFNβ.2,3 Acute autoimmune hepatitis (AIH) as a side effect of IFNβ therapy in MS is rare.2–4 There are no reported cases of IFNβ unmasking previously undiagnosed chronic AIH. We report a case in which chronic AIH only became symptomatic and diagnosed following the initiation of IFNβ therapy, and early recognition resulted in definitive therapy and an excellent outcome. A 43-year-old woman recently diagnosed with MS was started on IFNβ1a (Rebif) 22 μg TIW, and the dose was increased to 44 μg over 1 month as per routine protocol. She did not have any history of liver disease, alcohol abuse, or illicit drug use, and liver function tests (LFTs) were normal prior to treatment. Despite being told to have liver function tests performed 1 month after initiation of IFNβ, she was not heard from until about 6 weeks after the …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
